Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Oncology Reports|February 28, 2025
Transitioning from molecular methods to therapeutic methods: An in‑depth analysis of glioblastoma (Review)Hongxi Han, Aichao Du, Jinwen Li, et al.
Biology|October 27, 2022
The Characterization of the Tobacco-Derived Wild Tomato Mosaic Virus by Employing Its Infectious DNA CloneJinlong Yin, Xin Hong, Sha Luo, et al.
Developmental Cell|July 30, 2019
AAGAB Controls AP2 Adaptor Assembly in Clathrin-Mediated EndocytosisDaniel R Gulbranson, Lauren Crisman, MyeongSeon Lee, et al.
Plos Pathogens|December 8, 2020
A small molecule that mitigates bacterial infection disrupts Gram-negative cell membranes and is inhibited by cholesterol and neutral lipidsJamie L Dombach, Joaquin L J Quintana, Toni A Nagy, et al.
BMC Cancer|April 17, 2015
A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activityLily Liu, Haijia Yu, Xin Huang, et al.
Frontiers in Immunology|December 20, 2021
A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor ActivitiesXiaopei Cui, Huifeng Jia, Hong Xin, et al.
Cellular Signalling|February 12, 2024
IL-36 antagonism blunts the proliferation and migration of oral squamous cell carcinoma cellsZihui Li, Xiaoxin Zhang, Ke Li, et al.
International Journal of Biological Macromolecules|January 23, 2022
Structural and functional insights into a novel pre-clinical-stage antibody targeting IL-17A for treatment of autoimmune diseasesJin-Gen Xu, Huifeng Jia, Shi Chen, et al.
Frontiers in Immunology|January 30, 2026
Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibitionXi Zhu, Xiaopei Cui, Haijia Yu, et al.
Frontiers in Immunology|November 27, 2024
Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potencyXiaojuan Ma, Shuang Zhang, Xiaochen Ren, et al.
Pageof 9